Longmont biopharmaceutical company OnKure raises $495,000 in new funding

LONGMONT — OnKure Inc. — a spinoff of University of Colorado technology led by Array BioPharma co-founder Tony Piscopio — has raised $495,000 in new funding.

Longmont-based OnKure is developing compounds that inhibit cancer cell growth based on work by CU chemistry and biochemistry professor Xuedong Liu.

Neither Liu nor Piscopio, OnKure’s CEO, could be immediately reached for comment Tuesday.

SPONSORED CONTENT

Federal District Court Rules Corporate Transparency Act Unconstitutional . . . But Most Small Businesses Must Still Comply

Lyons Gaddis Real Estate and Business Attorney Cameron Grant shares important details of the Corporate Transparency Act (CTA).

The company disclosed the new funding in a document filed with the Securities and Exchange Commission. The filing indicated that the funding round, which includes seven investors so far, could grow as large as $1 million.

OnKure, incorporated in 2011, received a $250,000 grant from the state’s Bioscience Discovery Evaluation Grant Program in 2012.

Piscopio, who helped co-found publicly traded Array in 2008, left the company in 2005 to become chairman and CEO of Chemizon.